1054656-97-1

Upstream product

• 172939-22-9 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-L-erythro-pentose trimethylene dithioacetal 
• 172939-21-8 2,3-di-O-benzyl-4-deoxy-L-erythro-pentose trimethylene dithioacetal 
• 172939-23-0 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-aldehydo-L-erythro-pentose 
• 172939-18-3 methyl 2,3-di-O-benzyl-4-deoxy-β-L-erythro-pentopyranoside 
• 176198-99-5 methyl 4-O-[(4-methylphenyl)sulfonyl]-α-D-lyxopyranoside 
• 100-39-0 benzyl bromide 
• 58990-26-4 methyl 4-deoxy-β-L-erythro-pentopyranoside 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 173008-87-2 Acetic acid (3S,4R,5S)-3,4-bis-benzyloxy-6,6,6-trifluoro-5-hydroxy-hexyl ester 

Downstream Products

• 188892-82-2 C₂₆H₃₉F₃O₄Si₂ 
• 172939-25-2 3,4-di-O-benzyl-1,5-dideoxy-1,1,1-trifluoro-L-arabino-hexitol 
• 172939-24-1 6-O-acetyl-3,4-di-O-benzyl-1,5-dideoxy-1,1,1-trifluoro-L-arabino-hexitol 

Relevant academic research and scientific papers

A 5′-(trifluoromethyl)anthracycline glycoside: Synthesis of antitumor-active 7-O-(2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone

7-O-(2,6-Dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone (3), whose substituent at C-5′ is a lipophilic trifluoromethyl group, has been prepared by coupling of 3,4-di-O-acetyl-2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl bromide (20) wi